Traneurocin

cGP – Research Peptide | 1g

Other names: Cyclic glycine-proline; Cycloprolylglycine; NA-831

Specification:

• CAS: 3705-27-9
• Molar Mass: 54.169 g·mol⁻¹
• Sequence: Cyclo Gly-Pro
• Purity: ≥99%
• Form: Powder
• Amount: 1g per jar

About Traneurocin

Traneurocin (cyclo-gly-pro, cGP) is a stable cyclic dipeptide naturally generated from the N-terminal tripeptide of insulin-like growth factor-1 (IGF-1) and now formulated as the investigational drug NA-831. It has high oral bioavailability. Doses used in investigational studies suggest a dosage range from 10mg a day to 50mg a day, with 10mg/day proposed for mild cognitive impairment and Alzheimer's prevention, and doses in the 30mg-50mg range for mild-to-moderate Alzheimer's disease.

Because it retains the IGF-1 binding motif, cGP competes with IGF-1 for IGF-binding protein-3, boosting the fraction of free, bioactive IGF-1 while itself readily crossing the blood–brain barrier (≈7 h plasma half-life). Pre-clinical pharmacology also shows positive allosteric modulation of AMPA and GABA_A receptors and stimulation of brain-derived neurotrophic factor, aligning with reported neuro-protective, neurogenic and cognition-enhancing actions.   

Animal and cellular studies back up these mechanistic claims: cGP limits hydrogen-peroxide–induced oxidative injury in neuronal cultures, reduces infarct volume and improves functional recovery after experimental stroke, enhances spatial learning and synaptic plasticity in rodent tasks, and, in transgenic APP/PS1 mice,lowers amyloid plaque load while rescuing memory deficits. These effects are accompanied by promoted neurogenesis, vascular remodeling, and tempered inflammatory and apoptotic signaling, suggesting a broad cytoprotective profile that converges on IGF-1 normalization and downstream trophic cascades. 

Clinically, NA-831 has completed a Phase 1 safety study in mild cognitive impairment and has advanced to Phase 2 trials in Alzheimer’s disease, fragile X and Rett syndromes, Phase 1 in major depressive disorder, and a Phase 3 program targeting COVID-19–associated neuropathy. In parallel, observational work shows that a higher plasma cGP/IGF-1 ratio correlates with better cognition in ageing cohorts and with improved outcomes after ischemic stroke, positioning cGP both as a therapeutic and as a biomarker of IGF-1 bioavailability. To date, reported tolerability is excellent, and no serious adverse signals have emerged, but efficacy data remain preliminary pending completion of the ongoing registrational studies.